Analytical Data
-
Gene name
GLP1R
- Application
-
Alternative Names
GLP1R；Glucagon-like peptide 1 receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43220
-
Expression Region
24-145aa
-
AA Sequence
MKHHHHHHAS RPQGATVSLW ETVQKWREYR RQCQRSLTED PPPATDLFCN RTFDEYACWP DGEPGSFVNV SCPWYLPWAS SVPQGHVYRF CTAEGLWLQK DNSSLPWRDL SECEESKRGE RSSPEEQLLF LY
-
Molecular Weight
16 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GLP-1 receptor (GLP-1R) agonists have emerged as a pivotal focus in diabetes and obesity research due to their role in glucose metabolism and appetite regulation. Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by the intestines in response to food intake. It enhances insulin secretion from pancreatic beta cells while simultaneously inhibiting glucagon release, thus lowering blood glucose levels. Moreover, GLP-1 promotes satiety and slows gastric emptying, contributing to weight loss. However, the therapeutic potential of GLP-1 is limited by its rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). As a result, the development of GLP-1 receptor (GLP-1R) agonists, which mimic the action of GLP-1 and exhibit resistance to DPP-4, has gained significant attention. These recombinant proteins have shown efficacy in clinical settings, leading to improvements in glycemic control and weight management for individuals with type 2 diabetes and obesity. The structural and functional characterization of GLP-1R, as well as the exploration of its signaling pathways, are critical for enhancing the efficacy of these therapies and understanding their mechanisms of action. Ongoing research is focused on optimizing GLP-1R agonists to improve their pharmacokinetic profiles, minimize side effects, and expand their therapeutic applications beyond diabetes and obesity, making them an indispensable subject of study in metabolic disease management.
